Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Titilope Fasipe, MD, PhD
Researcher Co-Director
Sickle Cell Program
Texas Medical Center
6701 Fannin St., Ste. 15210.27
Houston, Texas, United States
Dr. Titilope Fasipe’s goals are shaped by her desire to help children facing the hardships of a blood disorder. She is intrigued by the clinical challenges of non-malignant hematologic diseases, wherein particular patients with sickle cell disease continue to have significant co-morbid complications and decreased lifespan. Furthermore, Dr. Titilope Fasipe has been long passionate about the psychosocial barriers to care experienced by children with sickle cell, especially during the transitional years.
In addition to her academic role, Dr. Fasipe’s is actively involved in various sickle cell-focused community efforts targeted at understanding these challenges. At the state level, she was appointed at the first Texas Sickle Cell Advisory Committee (2016-2018) by the Executive Commissioner of the Texas Health and Human Services. At the local level, she is the current chair of the Houston Sickle Cell Collaborative – a joint effort between the Houston Health Department and organizations vested in sickle cell disease.
Dr. Fasipe’s research interests are focused on understanding barriers to transitioning youth with sickle cell to adult care. She desires to improve readiness to transition through active training and mentorship programs. Additionally, she wants to understand the factors related to patients with high care utilization patterns, in particular those with recurrent pain encounters. Dr. Fasipe is working to provide interventions to help improve pain management and hence, decrease the burden of high utilization.
Representative Publications:
Regional Anesthesia for Sickle Cell Disease Vaso-Occlusive Crisis: A Single-Center Case Series
Spinal Cord Compression: An Unusual Sequela of Sickle Cell Disease
Hospital Use and Mortality in Transition-Aged Patients With Sickle Cell Disease
Related Content
-
Carla JonesAnyone affected by sickle cell disease k...
-
Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients Wi...Sancilio Pharmaceuticals Company, Inc. (...
-
Amber Yates, MDDr. Amber Yates is an Associate Director...
-
Crizanlizumab 5.0 mg/kg increased the time to first on-treatment sickle cell pain crisis (SCPC) and the likelihood o...Background: In the 52-week SUSTAIN stud...
-
When Cracking Down On Opioids Means Tougher Access For Sickle Cell PatientsMany people with sickle cell disease wil...
-
Sickle Cell PainSickle Cell Pain is a panoramic, in-dept...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...